Please assess the completion status of the following clinical trial:

Trial Title: Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed estrogen and/or progesterone receptor-positive breast cancer metastatic breast cancer~* Clinically determined evaluable disease~* Post-menopausal woman~* Previous clinical benefit from prior anti-estrogen therapies and subsequent failure of at least 2 prior endocrine therapies.~* May have had chemotherapy for adjuvant \&/or metastatic disease.~* May have had radiation therapy but not to the only site of disease.~* Ecog performance status \</= 2.~* Life expectancy of \> 6 months~Exclusion Criteria:~* Chemotherapy or radiotherapy within 1 week of beginning treatment in the clinical trial~* Brain metastasis~* Prior history of or active thrombophlebitis, deep venous thrombosis or pulmonary embolus~* Current vaginal bleeding~* Hypercalcemia or hypocalcemia~* History of or active hepatic adenoma~* No other malignancies within the past 5 years with the exception of curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estrace & Anastrozole (Type: EXPERIMENTAL): Estrace 10 mg three times a day for 3 months. After 3 months of estrace, the estrace will be stopped and anastrazole 1 mg daily will be administered

Based on this trial design, predict the completion outcome and termination type (if applicable).